Abstract
A short term (6-month) cost-effectiveness model has been developed to simulate
current medical practice and disease progression in patients with type 2
(non–insulin-dependent) diabetes mellitus uncontrolled by diet and exercise. The
model is based on decision-analytical techniques and includes probabilities of
switching between treatments, the reason for the switch and the most common
switch options. Effectiveness and economic measures are the 2 main outcomes.
In order to assess effectiveness, we use symptom-free days with acceptable
control (SFDACs), which represent each day of treatment without adverse events
or symptoms, and with acceptable control of glucose and lipids. For the economic
evaluation, only incremental costs incurred directly by a health insurance system
are considered.
This model should prove useful in the evaluation of new oral antidiabetic
agents, since the short term aim of antidiabetic therapy is to provide adequate
control in the absence of adverse effects and symptoms (a prerequisite for successful
long term treatment). Furthermore, short term analysis provides data for
comparing initial investment in drug therapy with potential savings over a longer
treatment period.
current medical practice and disease progression in patients with type 2
(non–insulin-dependent) diabetes mellitus uncontrolled by diet and exercise. The
model is based on decision-analytical techniques and includes probabilities of
switching between treatments, the reason for the switch and the most common
switch options. Effectiveness and economic measures are the 2 main outcomes.
In order to assess effectiveness, we use symptom-free days with acceptable
control (SFDACs), which represent each day of treatment without adverse events
or symptoms, and with acceptable control of glucose and lipids. For the economic
evaluation, only incremental costs incurred directly by a health insurance system
are considered.
This model should prove useful in the evaluation of new oral antidiabetic
agents, since the short term aim of antidiabetic therapy is to provide adequate
control in the absence of adverse effects and symptoms (a prerequisite for successful
long term treatment). Furthermore, short term analysis provides data for
comparing initial investment in drug therapy with potential savings over a longer
treatment period.
| Original language | English |
|---|---|
| Pages (from-to) | 317-326 |
| Number of pages | 10 |
| Journal | Pharmacoeconomics (Print) |
| Volume | 13 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1998 |
| Externally published | Yes |
Research programs
- EUR ESHPM 02
